Advertisement

Antihypertensive Therapy: Patient Selection and Special Problems

  • Barry J. Materson
Part of the Atlas of Heart Diseases book series (AD)

Abstract

Antihypertensive therapy clearly is effective in reducing the overall incidence of morbidity and mortality from cerebrovascular and cardiovascular disease. Hypertension, whether systolic, diastolic, or isolated systolic, is a major risk factor for vascular and target organ damage. Systolic blood pressure, increased pulse pressure, and high baseline heart rate are definite cardiovascular risk factors. Recent data support the concept that even very mildly elevated blood pressure is associated with a substantial risk. Nonpharmacologic therapy alone may not be as effective as drug therapy superimposed on nonpharmacologic therapy in reducing that risk. Nevertheless, the milder the average blood pressure of the treatment group, the greater the number of people who must be treated in order to prevent a single stroke or myocardial infarction. In an increasingly cost-conscious society, the emphasis is on targeting effective single-drug, low-cost therapy to patients who are at the highest risk. We have progressed only a little in this regard. We do not yet have sophisticated markers of enzyme and receptor genotypes, which may someday increase our specificity of who we treat and how we treat them. Nevertheless, we can no longer justify decerebrate “shotgun” antihypertensive therapy. Conversely, we are a long way from achieving 100% therapeutic precision. Well-informed, thoughtful caregivers now have the data to approach that ideal goal.

Keywords

Systolic Blood Pressure Left Ventricular Mass Antihypertensive Agent Antihypertensive Therapy Nonpharmacologic Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alderman MH: Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993, 119: 329–335.PubMedGoogle Scholar
  2. 2.
    Ménard J, Chatellier G: Mild hypertension: the mysterious viability of a faulty concept. J Hypertens 1995, 13: 1071–1077.PubMedCrossRefGoogle Scholar
  3. 3.
    Medical Research Council Working Party: MRC trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304: 405–412.CrossRefGoogle Scholar
  4. 4.
    National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 1993, 153: 186–208.CrossRefGoogle Scholar
  5. 5.
    Johnston DW: The behavioral control of high blood pressure. Curr Psychol Res Rev 1987, 6: 99–114.CrossRefGoogle Scholar
  6. 6.
    Svendsen OL, Hassager C, Christiansen C: Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med 1993, 95: 131–140.PubMedCrossRefGoogle Scholar
  7. 7.
    Klatsky AL, Friedman GD, Siegelaub AB, et al.: Alcohol consumption and blood pressure: Kaiser-Permanente Multiphasic Health Examination Data. N Engl J Med 1977, 296: 1194–1200.PubMedCrossRefGoogle Scholar
  8. 8.
    Maheswaran R, Gill JS, Davies P, et al.: High blood pressure due to alcohol: a rapidly reversible effect. Hypertension 1991, 17: 787–792.PubMedCrossRefGoogle Scholar
  9. 9.
    Verdecchia P, Schillaci G, Borgioni, et al.: Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995, 13: 1209–1215.PubMedCrossRefGoogle Scholar
  10. 10.
    Cutler JA, Follmann D, Elliott P, et al.: An overview of randomized trials of sodium reduction and blood pressure. Hypertension 1991, 17(suppl I): 27–33.CrossRefGoogle Scholar
  11. 11.
    He J, Ogden LG, Vupputuri LA, et al.: Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999, 282: 2027–2034.PubMedCrossRefGoogle Scholar
  12. 12.
    MacGregor GA, Markandu ND, Sagnella GA, et al.: Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 1989, 2: 1244–1247.PubMedCrossRefGoogle Scholar
  13. 13.
    Tabuchi Y, Ogihara T, Gotoh, et al.: Hypotensive mechanism of potassium supplementation in salt-loaded patients with essential hypertension. J Clin Hypertens 1985, 2: 145–152.Google Scholar
  14. 14.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Urinary and serum electrolytes in untreated black and white hypertensives. J Chronic Dis 1987, 40: 839–847.CrossRefGoogle Scholar
  15. 15.
    Materson BJ: Diuretic-associated hypokalemia. Arch Intern Med 1985, 145: 1966–1967.PubMedCrossRefGoogle Scholar
  16. 16.
    Khaw K-T, Barrett-Connor E: Dietary potassium and stroke-associated mortality: a 12-year prospective population study. N Engl J Med 1987, 316: 235–240.PubMedCrossRefGoogle Scholar
  17. 17.
    Harrington JT, Isner JM, Kassirer JP: Our national obsession with potassium. Am J Med 1982, 73: 155–159.PubMedCrossRefGoogle Scholar
  18. 18.
    Grimm RH Jr, Neaton JD, Elmer PJ, et al.: The influence of oral potassium chloride on blood pressure in hypertensive men on a low-sodium diet. N Engl J Med 1990, 322: 569–574.PubMedCrossRefGoogle Scholar
  19. 19.
    Stamler R: Implications of the INTERSALT study. Hypertension 1991, 17(suppl I): I-16–I-20.CrossRefGoogle Scholar
  20. 20.
    Steptoe A, Fieldman G, Evans O, et al.: Control over work place, job strain and cardiovascular responses in middle-aged men. J Hypertens 1993, 11: 751–759.PubMedCrossRefGoogle Scholar
  21. 21.
    Sowers JR, Zemel MB, Zemel PC, et al.: Calcium metabolism and dietary calcium in salt sensitive hypertension. Am J Hypertens 1991, 4: 557–563.PubMedGoogle Scholar
  22. 22.
    Neaton JD, Grimm RH, Prineas RJ, et al.: The Treatment of Mild Hypertension Study Research Group. JAMA 1993, 270: 713–724.PubMedCrossRefGoogle Scholar
  23. 23.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension: I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982, 248: 1996–2003.CrossRefGoogle Scholar
  24. 24.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Racial differences in response to low-dose Captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982, 14(suppl 2): 97–101.CrossRefGoogle Scholar
  25. 25.
    Saunders E, Weir MR, Kong BW, et al.: A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990, 150: 1707–1713.PubMedCrossRefGoogle Scholar
  26. 26.
    Applegate WB, Phillips HL, Schnaper H, et al.: A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med 1991, 151: 1817–1823.PubMedCrossRefGoogle Scholar
  27. 27.
    Wassertheil-Smoller S, Oberman A, Blaufox MD, et al.: The Trial of Antihypertensive Interventions and Management (TAIM) Study: final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992, 5: 37–44.PubMedGoogle Scholar
  28. 28.
    Materson BJ, Reda DJ, Cushman WC, et al.: Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328: 914–921.PubMedCrossRefGoogle Scholar
  29. 29.
    Materson BJ, Reda DJ, Preston RA, et al.: Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med 1995, 55: 1757–1762.CrossRefGoogle Scholar
  30. 30.
    Materson BJ, Reda DJ, Cushman WC, et al.: Results of combination anti-hypertensive therapy after failure of each of the components. J Human Hypertens 1995, 9: 791–795.Google Scholar
  31. 31.
    Gottdiener JS, Reda DJ, Massie BM, et al.: Effect of single-drug therapy on reduction of left ventricular mass in milde to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affirs Cooperative Study Group on Antihypertensive Agents. Circulation 1997, 95: 2007–2014.PubMedCrossRefGoogle Scholar
  32. 32.
    Lakshman MR, Reda DJ, Materson BJ, et al.: Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affirs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999, 159: 551–558.PubMedCrossRefGoogle Scholar
  33. 33.
    Preston RJ, Materson BJ, Reda DJ, et al.: Age-subgoup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affirs Cooperative Study Group on Antihypertensive Agents. JAMA 1998, 280: 1168–1172.PubMedCrossRefGoogle Scholar
  34. 34.
    Ravid M, Lang R, Rachmani R, Lishner M: Long-term reno-protective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156: 286–289.PubMedCrossRefGoogle Scholar
  35. 35.
    Kirby RS: Doxazosin in benign prostatic hyperplasia: effects of blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995, 46: 182–186.PubMedCrossRefGoogle Scholar
  36. 36.
    Markovitz JH, Matthews KA, Kännel WB, et al.: Psychological predictors of hypertension in the Framingham Study. Is there tension in hypertension? JAMA 1993, 270: 2439–2443.PubMedCrossRefGoogle Scholar
  37. 37.
    Reaven GM, Clinkingbeard C, Jeppesen J, et al.: Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995, 8: 461–466.PubMedCrossRefGoogle Scholar
  38. 38.
    Materson BJ: Hypertension and concomitant disease: guidelines for treatment. Drug Therapy 1985, 15: 177–188.Google Scholar
  39. 39.
    Croog SH, Levine S, Testa MA, et al.: The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986, 314: 1657–1664.PubMedCrossRefGoogle Scholar
  40. 40.
    Testa MA, Anderson RB, Nackley JF, et al and the Quality-of-Life Hypertension Study Group: Quality of life and antihypertensive therapy in men: a comparison of Captopril with enalapril. N Engl J Med 1993, 328: 907–913.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Barry J. Materson

There are no affiliations available

Personalised recommendations